Although several of the pathways discussed—particularly those involving BDNF–TrkB signaling—are hypothesized to contribute to recovery in neurodegenerative and cerebrovascular disorders, current evidence remains largely preclinical, and consistent links between molecular modulation and clinical symptom improvement have yet to be demonstrated. This evidence concerns the gene NTRK2 and cerebrovascular disorder.